Steadybase.

Geron Corp.

Website LinkedIn Latest 10-K
  • GERN · Nasdaq
  • Pharmaceutical Preparations
  • Foster City, CA
  • 258 employees
  • CIK 0000886744

Updated from SEC filings through

Top things to know

Executives

What leadership is saying

“Another quarter of strong RYTELO demand growth reinforces our confidence in the LR-MDS commercial opportunity and our ability to reach more second-line patients. Increased demand growth is being driven by the community practices which, in our view, indicates the potential for RYTELO to have a long growth runway in the U.S.”

Harout Semerjian, President and Chief Executive Officer of Geron
Earnings press release (8-K Ex. 99.1), filed November 4, 2026

Geron Corp is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Foster City, CA. It trades as GERN on Nasdaq. Revenue was $237K in the fiscal year ending December 31, 2023, -60.2% from the year before. It reported about 258 employees. Harout Semerjian is President & CEO.

Five-year financials

MetricFY2025FY2024FY2023FY2022FY2021
Revenue Not on file Not on file $237K
10-K, 2024-02-28
$596K
10-K, 2024-02-28
$1.4M
10-K, 2024-02-28
Operating income -$68.6M
10-K, 2026-03-02
-$174M
10-K, 2026-03-02
-$194M
10-K, 2026-03-02
-$139M
10-K, 2025-02-27
-$114M
10-K, 2024-02-28
SG&A $159M
10-K, 2026-03-02
$146M
10-K, 2026-03-02
$69.1M
10-K, 2026-03-02
$43.6M
10-K, 2025-02-27
$29.7M
10-K, 2024-02-28
Net income -$83.5M
10-K, 2026-03-02
-$175M
10-K, 2026-03-02
-$184M
10-K, 2026-03-02
-$142M
10-K, 2025-02-27
-$116M
10-K, 2024-02-28

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Harout Semerjian Harout Semerjian President & CEO Form 4, November 16, 2026
John A. Scarlett, M.D. Named in proxy
bio: Former Chairman of the Board, President and Chief Executive Officer
DEF 14A, April 7, 2026
Michelle J. Robertson Michelle J. Robertson Named in proxy
bio: Executive Vice President, Finance, Chief Financial Officer, Treasurer and Interim Secretary
DEF 14A, April 7, 2026
Timothy Williams EVP and Chief Legal Officer Form 4, April 14, 2026
Andrew J. Grethlein, Ph.D. Named in proxy
bio: Former Executive Vice President, Chief Operating Officer
DEF 14A, April 7, 2026
James Ziegler Named in proxy
bio: Former Executive Vice President, Chief Commercial Officer
DEF 14A, April 7, 2026
Joseph Eid, M.D. Named in proxy
bio: Executive Vice President, Research & Development, Chief Medical Officer
DEF 14A, April 7, 2026
Ahmed ElNawawi Executive Vice President, Chief Commercial Officer 10-K, March 2, 2026
Dawn C. Bir Dawn C. Bir Board member (per proxy)
bio: director
DEF 14A, April 7, 2026
Constantine Chinoporos Board member (per proxy)
bio: director
DEF 14A, April 7, 2026
Elizabeth G. O'Farrell Board member (per proxy)
bio: director
DEF 14A, April 7, 2026
John F. McDonald Board member (per proxy)
bio: director
DEF 14A, April 7, 2026
Patricia S. Andrews Board member (per proxy)
bio: director
DEF 14A, April 7, 2026
Robert J. Spiegel, M.D., FACP Board member (per proxy)
bio: director
DEF 14A, April 7, 2026
Susan M. Molineaux, Ph.D. Board member (per proxy)
bio: director
DEF 14A, April 7, 2026
V. Bryan Lawlis, Ph.D. Board member (per proxy)
bio: director
DEF 14A, April 7, 2026

What Geron Corp does

Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO ® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California.

Press release "About" paragraph, 10-K for the year ending October 28, 2026

Shares and governance

Shares outstanding 644.2 million (as of October 30, 2026) 10-Q, November 4, 2026
Public float $861M (as of June 30, 2025) 10-K, March 2, 2026
Reportable segments 1 (period ending September 30, 2026) 10-Q, November 4, 2026
Latest proxy statement Meeting May 20, 2026 (filed April 7, 2026) DEF 14A, April 7, 2026
Auditor Ernst & Young LLP (Iselin, New Jersey) Latest 10-K

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
November 16, 2026 Timothy Williams
EVP and Chief Legal Officer
Buy 12,000 $11K Form 4, November 16, 2026
November 13, 2026 Harout Semerjian
President & CEO
Buy 53,500 $51K Form 4, November 16, 2026
February 18, 2026 Michelle Robertson
EVP, CHIEF FINANCIAL OFFICER
Sale 9,855 $19K Form 4, February 19, 2026

Recent 8-K events

Frequently asked questions about Geron Corp

What does Geron Corp do?
In its own words, from Item 1 of its 10-K: "Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO ® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California."
What is Geron Corp's revenue?
$237K for the fiscal year ending December 31, 2023, from its 10-K filed February 28, 2024.
Is Geron Corp profitable?
Geron Corp reported net income of -$184M for the fiscal year ending December 31, 2023.
How many employees does Geron Corp have?
About 258 as of December 31, 2025, as stated in its annual report.
Who is the CEO of Geron Corp?
Harout Semerjian, President & CEO, as named in a 4 filed November 16, 2026.
Where is Geron Corp headquartered?
Foster City, CA.
What is Geron Corp's stock ticker?
GERN on Nasdaq.
What industry is Geron Corp in?
Pharmaceutical Preparations, SIC code 2834.
What is Geron Corp's website?
geron.com.
When does Geron Corp report earnings next?
February 3, 2027. This is an estimate from past filing dates, not a confirmed date.
Is Geron Corp a public company?
Yes. Geron Corp files with the SEC under CIK 0000886744 and trades as GERN.
Who audits Geron Corp?
Ernst & Young LLP, Iselin, New Jersey, as named in its latest annual report (10-K).
How many shares of Geron Corp are outstanding?
644.2 million shares as of October 30, 2026, from its 10-Q filed November 4, 2026.
What is Geron Corp's public float?
$861M as of June 30, 2025, as reported on the cover of its 10-K filed March 2, 2026.
How many business segments does Geron Corp report?
1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 4, 2026.
When is Geron Corp's annual shareholder meeting?
May 20, 2026, per its proxy statement (DEF 14A) filed April 7, 2026.
Have Geron Corp insiders traded stock recently?
Since February 18, 2026, officers and directors reported 1 open-market sale worth about $19K and 2 purchases worth about $62K on Forms 4 and 5. The most recent: Timothy Williams (EVP and Chief Legal Officer) bought 12,000 shares on November 16, 2026.